260 related articles for article (PubMed ID: 15712070)
21. [Detection and the production mechanism of antinuclear antibodies (ANA) and anti-liver/kidney microsomal tpe 1 antibodies (anti-LKM1) in patients with chronic hepatitis C].
Bai L; Lu HY; Feng ZR; Yu M; Li WG; Gong WB; Zhao NE; Xu XY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):278-81. PubMed ID: 20108773
[TBL] [Abstract][Full Text] [Related]
22. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
23. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
24. Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2018 Oct; 66(5):605-610. PubMed ID: 30220012
[TBL] [Abstract][Full Text] [Related]
25. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy.
Jorquera F; Almar M; Díaz-Golpe V; Olcóz JL; García-Fernández A; González-Gallego J
Am J Gastroenterol; 2001 Aug; 96(8):2456-61. PubMed ID: 11513190
[TBL] [Abstract][Full Text] [Related]
26. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
27. Autoantibody profile in individuals with chronic hepatitis C.
Marconcini ML; Fayad L; Shiozawa MB; Dantas-Correa EB; Lucca Schiavon Ld; Narciso-Schiavon JL
Rev Soc Bras Med Trop; 2013; 46(2):147-53. PubMed ID: 23740063
[TBL] [Abstract][Full Text] [Related]
28. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
29. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
30. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
[TBL] [Abstract][Full Text] [Related]
31. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
[TBL] [Abstract][Full Text] [Related]
33. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
34. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
Hass HG; Klein R; Nehls O; Kaiser S
J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
[TBL] [Abstract][Full Text] [Related]
35. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
[TBL] [Abstract][Full Text] [Related]
36. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
37. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
Narciso-Schiavon JL; Freire FC; Suarez MM; Ferrari MV; Scanhola GQ; Schiavon Lde L; Carvalho Filho RJ; Ferraz ML; Silva AE
Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):350-6. PubMed ID: 20611005
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial results of peginterferons in combination with ribavirin.
Craxi A; Licata A
Semin Liver Dis; 2003; 23 Suppl 1():35-46. PubMed ID: 12934167
[TBL] [Abstract][Full Text] [Related]
39. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
40. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
Mauss S; Berger F; Schober A; Moog G; Heyne R; John C; Pape S; Hueppe D; Pfeiffer-Vornkahl H; Alshuth U
J Viral Hepat; 2013 Apr; 20(4):e72-7. PubMed ID: 23490392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
